Optimization of Anthralin Microemulgel Targeted Delivery for Psoriasis and Acne
Molecules · 2025
DOI: 10.3390/molecules30122629 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2025. Verfasst von Samiksha Sakarkar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, School of Health Sciences and Technology, Dr. Vishwanath Karad MIT World Peace University, Kothrud, Pune 41103…. Hauptthemen laut MEDLINE: Psoriasis, Acne Vulgaris, Anthralin, Anti-Bacterial Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Princess Nourah bint Abdulrahman University, Princess Nourah bint Abdulrahman University Researchers.
Abstract (Originalsprache)
Background
Anthralin is known for its efficacy in treating psoriasis and acne, possessing poor solubility. Addressing these limitations, the present study endeavors to develop a microemulgel formulation of anthralin aimed at enhancing solubility.
Method
The solubility study was performed in various solvents. An o/w (oil-in-water) emulsion was formed using the water titration method, which was optimized by statistical experimental design half-run CCD. The final optimized batch was evaluated for physicochemical and in vitro properties Result: The final optimized batch showed a particle size (PS) of 417 nm, −25.2 mV zeta potential (ZP) and pH 5.8, which remained stable upon centrifugation, heating–cooling and freeze–thawing cycle. Furthermore, microemulsion with Carbopol 943 5% w/v was selected as the gel base for the formation of microemulgel characterized by PS, ZP, pH, and viscosity of 230 nm, −50.6 mV, 6.9 and 14,200 cps, respectively, that ensured it a high enough stability. In silico molecular docking between ligand and protein provides the binding energies validating the interaction. Hence, the in silico study was performed for psoriasis and P. acne proteins. An in vitro antibacterial activity study on Propionibacterium revealed a significant efficiency of the formulation and MTT assay using L929 cell line in the presence of the drug-loaded microemulgel indicated an inhibition of growth proving that formulation has anti-psoriatic activity.
Conclusions
Combination therapy with Clindamycin might improve efficacy while reducing antibiotic resistance risks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, School of Health Sciences and Technology, Dr. Vishwanath Karad MIT World Peace University, Kothrud, Pune 411038, India.
- Department of Electrical Engineering, College of Engineering, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia.
- Department of Food Science and Nutrition, University of Leeds, Leeds LS2 9JT, UK.
- Department of Information Systems, College of Computer and Information Sciences, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia.
ORCID-Profile: Swati Jagdale, Shrikant Dargude, Anuruddha Chabukswar, Shabana Urooj, Hanan Abdullah Mengash
Förderung
- Princess Nourah bint Abdulrahman University
- Princess Nourah bint Abdulrahman University Researchers
Zitieren
APA
Sakarkar, S., Jagdale, S., Dargude, S., Chabukswar, A., Urooj, S., Bilal, A., & Mengash, H. A. (2025). Optimization of Anthralin Microemulgel Targeted Delivery for Psoriasis and Acne. Molecules. https://doi.org/10.3390/molecules30122629
Vancouver
Sakarkar S, Jagdale S, Dargude S, Chabukswar A, Urooj S, Bilal A, et al. Optimization of Anthralin Microemulgel Targeted Delivery for Psoriasis and Acne. Molecules. 2025. doi:10.3390/molecules30122629
BibTeX
@article{Sakarkar2025,
author = {Sakarkar, Samiksha and Jagdale, Swati and Dargude, Shrikant and Chabukswar, Anuruddha and Urooj, Shabana and Bilal, Anusha and Mengash, Hanan Abdullah},
title = {Optimization of Anthralin Microemulgel Targeted Delivery for Psoriasis and Acne},
journal = {Molecules},
year = {2025},
doi = {10.3390/molecules30122629}
}
EUVIMED